FDA Post-Marketing Study Compliance Efforts To Get HHS OIG Review
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS watchdog will also continue its look at generic drug facility inspections and supply chain oversight, according to its fiscal year 2015 work plan.